LUTATHERA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUTATHERA (LUTATHERA).
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog that binds to somatostatin receptors (primarily subtype 2) with high affinity, resulting in internalization and intracellular retention of the radionuclide. The beta particle emission from Lu-177 causes DNA damage and cell death in somatostatin receptor-positive tumor cells.
| Metabolism | Lutetium Lu 177 dotatate is not metabolized; it is a radiopharmaceutical that decays via beta minus emission to stable hafnium-177. The drug is cleared primarily by renal excretion. |
| Excretion | Renal excretion: approximately 50% of administered radioactivity excreted in urine within 24 hours, primarily as intact LUTATHERA and metabolites; fecal excretion: <5%. |
| Half-life | Terminal elimination half-life: approximately 3.5 days (84 hours) for the radioactive component (177Lu); clinically, this allows for prolonged tumor exposure and once-every-8-weeks dosing. |
| Protein binding | Approximately 30% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution: approximately 0.5 L/kg, indicating distribution into extracellular fluid and tissues, including tumor sites. |
| Bioavailability | Not applicable; LUTATHERA is administered intravenously, thus bioavailability is 100% by IV route. |
| Onset of Action | Intravenous administration: clinical response (e.g., tumor shrinkage, symptom improvement) typically observed after 2-3 treatment cycles (16-24 weeks); objective responses may be seen earlier in some patients. |
| Duration of Action | Duration of therapeutic effect: variable, with median progression-free survival of approximately 8-9 months in neuroendocrine tumors; duration limited by tumor re-growth and cumulative radiation toxicity. |
7.4 GBq (200 mCi) intravenously every 8 weeks for 4 doses, with concomitant amino acid infusion for renal protection.
| Dosage form | SOLUTION |
| Renal impairment | Creatinine clearance ≥30 mL/min: no adjustment. <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh B or C: caution; no specific dose adjustment established, consider risk-benefit. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No dose adjustment required; elderly patients may have reduced renal function; monitor creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUTATHERA (LUTATHERA).
| Breastfeeding | It is unknown if lutetium Lu 177 dotatate is excreted in human milk. Due to the potential for serious adverse reactions from radiation exposure, breastfeeding is not recommended during treatment and for at least 2.5 months after the last dose. M/P ratio is not available. |
| Teratogenic Risk | LUTATHERA (lutetium Lu 177 dotatate) is a radiopharmaceutical. Based on its mechanism of action and radiation exposure, it is contraindicated during pregnancy. Fetal risks include severe teratogenicity, growth retardation, and fetal death due to radiation exposure at any trimester. No adequate human studies exist. |
■ FDA Black Box Warning
WARNING: RADIATION EXPOSURE. Lutathera emits ionizing radiation, which can increase the risk of cancer, leukemia, or other malignancies. Radiation exposure to patients, family members, and medical personnel must be minimized. Follow institutional radiation safety protocols.
| Serious Effects |
["Hypersensitivity to lutetium Lu 177 dotatate or any of its components"]
| Precautions | ["Myelosuppression: severe and life-threatening neutropenia, thrombocytopenia, and anemia","Renal toxicity: acute renal failure or chronic kidney disease; renal function must be monitored","Hepatotoxicity: hepatic impairment and liver failure","Neuroendocrine hormonal crisis: flushing, hypotension, bronchospasm, or other symptoms due to release of vasoactive substances","Pulmonary fibrosis: potential risk","Secondary malignancies: including myelodysplastic syndrome, acute leukemia, and other cancers","Radiation exposure: protect patients, family, and healthcare workers"] |
Loading safety data…
| Fetal Monitoring | Pregnancy testing is required before treatment for women of reproductive potential. Female patients should use effective contraception during treatment and for 7 months after the final dose. Monitor for signs of radiation toxicity, including bone marrow suppression and nephrotoxicity. Fetal monitoring is not applicable as it is contraindicated in pregnancy. |
| Fertility Effects | LUTATHERA may impair fertility in both males and females. Radiation exposure can cause ovarian failure in women and azoospermia or oligospermia in men. These effects may be irreversible. Long-term fertility preservation options should be discussed before treatment. |